29 commercial payer policies list J2351. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
29 policies from 18 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrevus (Ocrelizumab) and Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) | Jan 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Ocrevus (Ocrelizumab) and Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title |
| Ocrevus (Ocrelizumab) and Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) – Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq | Apr 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq | Apr 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq | Apr 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq | Apr 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrevus (ocrelizumab) Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) | Feb 1, 2026 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Ocrevus (ocrelizumab) Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)Effective 02/01/2025 - 01/31/2026 | Feb 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrevus (Ocrelizumab) and Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) | Jan 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (e.g., Ocrevus) and Ocrelizumab with Hyaluronidase (e.g., Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Multiple Sclerosis Products:(Ocrelizumab [Ocrevus], Ocrelizumab and Hyaluronidase-ocsq [Ocrevus Zunovo], Ublituximab-xiiy [Briumvi]) | Feb 10, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus) and Ocrevus Zunovo | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus), Ocrelizumab/Hyaluronidase-ocsq (Ocrevus Zunovo); CP.PHAR.335 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus) and Ocrelizumab hya-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| 00559 ocrelizumab (Ocrevus) ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrelizumab (Ocrevus, Ocrevus Zunovo) (PG235, Ver. 6) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2351 |
|---|---|---|
| Ocrevus (Ocrelizumab) and Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) | Jan 1, 2026 | Covered |